COPD

Flu vaccination reduced influenza-related hospitalizations by 38% among patients with COPD.

UAB investigators sought to learn if neutrophil elastase exists in an exosomal form, and whether these exosomes could potentially bypass alpha1-antitrypsin inhibition to contribute to COPD.

About 1 in 7 heart failure patients have COPD, which can lead to a 30% increase in risk of hospitalization and death.

Tobacco farm region physicians face the challenges of culture, law, and education in improving cessation.

About half of all patients with COPD suffer from serious adverse events following a hospital discharge, yet physicians cannot accurately distinguish which are at risk.

Some of the most common symptoms of COPD drive anxiety in its patients. An England-based study sought out a cost-effective response.

With no distinctive definition for what constitutes asthma-COPD overlap, clinicians are advising both diseases become diagnosed and treated differently.

Living in rural areas and coal burning for heat were found to be risk factors for developing COPD.

Pulmonary rehab is a program of exercise and education that is proven to increase exercise capacity, reduce symptoms, and elevate quality of life for patients, and is recommended in all major professional society guidelines in the US, Europe, and Canada.

The Spiration Valve System treats emphysema by blocking air from entering diseased areas of the lung.

The FDA has approved revefenacin (YUPELRI) for the maintenance treatment of chronic obstructive pulmonary disease.

Until recently, studies of systemic corticosteroids in pneumonia have yielded contradicting results, while studies in acute exacerbation of COPD have shown significant benefits.

The most reliable practice for helping a patient quit is comprehensive, and catered to their medical, physical, and financial goals.

Patients with inappropriate medication use lived farther from their preferred pharmacy than those with appropriate use—a median distance difference of just more than 1 mile.

The interleukin pathway-targeting monoclonal antibody has been previously approved for adult atopic dermatitis, and is being considered for a handful more inflammatory or allergic conditions.